Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 9Thoracic 6Head & Neck 6Genitourinary 5Gastrointestinal 5Breast 3Other solid neoplasm 2Gynecologic 2Myeloid 1Lymphoid 1Endocrine 1

Conditions

Breast Neoplasms 16Triple Negative Breast Neoplasms 11Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 6Urinary Bladder Neoplasms 4Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Neoplasm Metastasis 3Melanoma 3Head and Neck Neoplasms 3Carcinoma, Merkel Cell 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Neoplasm, Residual 1Mesothelioma, Malignant 1Gastrointestinal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 44Cyclophosphamide 21Nivolumab 18fludarabine 10durvalumab 8Paclitaxel 8Magnetic Resonance Spectroscopy 8Interleukin-2 8Docetaxel 8aldesleukin 7Radiosurgery 7Ipilimumab 7spartalizumab 6poly ICLC 6fludarabine phosphate 6atezolizumab 6Specimen Handling 6Radiotherapy 6Carboplatin 6cemiplimab 5Drug Therapy 5Cisplatin 5Biopsy 5Temozolomide 4Immune Checkpoint Inhibitors 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3avelumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × avelumab × Breast × Clear all
NCT02554812 2024-07-30

JAVELIN Medley

Pfizer

Phase 1/2 Terminated
409 enrolled 108 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT01772004 2021-12-20

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

EMD Serono

Phase 1 Completed
1,756 enrolled 59 charts
BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡